Clinical trial · Interventional
Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Phase 2 Study of Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
NCT00408070CI-TRIAL-00031986terminatedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Did not meet accrual goals.
Summary
Brief summary (as posted)
The primary objective is to determine whether the addition of bevacizumab to a regimen of carboplatin plus paclitaxel significantly improves Progression Free Survival (PFS) for patient with Stage III suboptimally cytoreduced or Stage IV ovarian, primary peritoneal or fallopian tube carcinomas.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Fallopian Tube Cancer | Malignant Fallopian Tube Neoplasm | ALIAS | 0.90 |
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
| Peritoneal Cancer | Malignant Peritoneal Neoplasm | ALIAS | 0.90 |
| Stage 3 Cancer | — | UNRESOLVED | — |
| Stage 4 Cancer | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bevacizumab | Drug | Bevacizumab | ALIAS |
| Carboplatin | Drug | Carboplatin | ALIAS |
| Paclitaxel | Drug | Paclitaxel | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- I
- description
- This is a single Arm study. Two of the study drugs used are non-experimental. One of the study drugs is experimental.
- interventionNames
- Drug: Bevacizumab
- Drug: Carboplatin
- Drug: Paclitaxel
Primary outcomes (1)
- measure
- Progression Free Survival Rate at 9 Months
- timeFrame
- 9 months
- description
- This Outcome is measuring the number of particpants who have survived.
Secondary outcomes (4)
- measure
- Response to Treatment (Clinical/Pathological)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: * diagnosis of primary peritoneal carcinoma, fallopian tube epithelial ovarian carcinoma, * stage III suboptimal surgery or biopsy, * stage IV disease * no prior chemotherapy Exclusion Criteria: * unstable heart conditions * high blood pressure * vascular disorders * bleeding problems
References
Publications (0)
Data not yet available
No reference posted for this study.